USNA screens cheap (7.7x forward P/E) with a favorable 5.74x asymmetric risk/reward and a near-term earnings catalyst off a perfect recent beat streak, but sits just under the $400M investable-universe threshold with a failed momentum gate and an elevated put/call ratio (1.75) ahead of the report.
Thesis pillars
- Cheap Forward Multiple—
- Earnings Catalyst Asymmetry—
- Elevated Pre Earnings Options Positioning—
- +1 more pillar — see the Why tab for full reasoning
USANA Health Sciences, Inc. (USNA) Stock Analysis
Inst Constrain edge
Consumer Defensive · Packaged Foods
Sell if holding. Momentum 1.7/10 is below the 5.0 floor at $16.93 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Geographic: outside the United States (75.7%); Weak overall score: 4.7/10.
USANA Health Sciences develops and manufactures nutritional supplements, functional foods, and personal care products sold through a direct-selling network of Brand Partners and Preferred Customers, plus the Hiya children's-vitamin subscription business and the Rise protein-bar... Read more
Sell if holding. Momentum 1.7/10 is below the 5.0 floor at $16.93 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Geographic: outside the United States (75.7%); Weak overall score: 4.7/10. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.7/10, moderate confidence.
Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
About USANA Health Sciences, Inc.
About USANA Health Sciences, Inc.
USANA Health Sciences counted approximately 387,000 active Customers in its core nutritional business and 181,700 active Monthly Subscribers in its Hiya children's-vitamin subscription unit as of the 2025 and January 2026 fiscal year-ends, respectively, generating $925 million in net sales. Mainland China is the company's largest market, contributing approximately 41.3% of net sales, while operations span 25 geographic markets and roughly 75.7% of net sales originate outside the United States.
USANA's core nutritional segment compensates Brand Partners under a multilevel Compensation Plan that the company revised in 2025 to reward earlier sales, customer, and team growth, while Preferred Customers purchase strictly for personal use without resale rights. The Hiya subsidiary, majority-owned since a December 2024 acquisition, sells children's vitamins primarily through a subscription model in the United States and is expanding into Canada and the United Kingdom and into retail distribution during 2026. USANA manufactures approximately 56% of its products in-house at a Salt Lake City, Utah facility and a 54,000-square-foot food-products plant, while its BabyCare subsidiary manufactures the majority of China-market products at facilities in Beijing and Tianjin. Product research and development spending totaled $10.7 million in fiscal 2025, down from $11.6 million in fiscal 2024, funding more than 15 new or upgraded product launches during the year.
Show full overview
USANA's compensation-plan structure sits squarely inside an active regulatory review: the FTC issued a Notice of Proposed Rulemaking in 2025 that would require direct-selling companies to substantiate earnings claims in writing, while an accompanying Advance Notice considers further limits on recruiting and compensation that could apply industry-wide. In China, BabyCare operates under a business model the company designed to fit local direct-selling law, but the 10-K states plainly that the Chinese government has not approved BabyCare's model, compensation plan, or operations, leaving the segment that drives roughly 41% of consolidated net sales subject to reinterpretation by provincial and municipal regulators at any time.
From USANA Health Sciences, Inc.'s most recent 10-K filing, extracted July 26, 2026.
Recent developments
updated 2026-08-05Recent Developments — USANA Health Sciences, Inc.
Latest news
- NEWS Usana Health Sciences Lowers FY2026 Adj EPS Guidance from $1.95-$2.29 to $0.76 vs $2.12 Est; Lowers FY2026 Sales Guidanc — benzinga Aug 4, 2026 negative
- NEWS Usana Health Sciences Q2 Adj. EPS $(0.07) Misses $0.43 Estimate, Sales $223.273M Miss $235.003M Estimate — benzinga Aug 4, 2026 negative
Generated 2026-08-05T14:55:38Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMGeographicChina41%10-K Item 1: 'Mainland China (“China”) is our largest market and single largest source of revenue, representing approximately 41.3% of net sales and approximately 49.9% of core nutritional active Customers.'
- HIGHGeographicoutside the United States76%10-K Item 1: 'In 2025, net sales outside of the United States represented approximately 75.7% of consolidated net sales.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 1.7/10 is below the 5.0 floor at $16.93 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Geographic: outside the United States (75.7%); Weak overall score: 4.7/10. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $15.97. Score 4.7/10, moderate confidence.
Take-profit target: $33.15 (+96.7% upside). Prior stop was $15.97. Stop-loss: $15.97.
Concentration risk — Geographic: outside the United States (75.7%); Weak overall score: 4.7/10; Weak growth.
USANA Health Sciences, Inc. trades at a P/E of 45.6 (forward 8.2). TrendMatrix value score: 8.0/10. Verdict: Sell.
6 analysts cover USNA with a consensus score of 2.2/5. Average price target: $39.
What does USANA Health Sciences, Inc. do?USANA Health Sciences develops and manufactures nutritional supplements, functional foods, and personal care products...
USANA Health Sciences develops and manufactures nutritional supplements, functional foods, and personal care products sold through a direct-selling network of Brand Partners and Preferred Customers, plus the Hiya children's-vitamin subscription business and the Rise protein-bar brand, across 25 geographic markets. The company generated $925 million in net sales in 2025 from about 387,000 active core-nutritional Customers, with Mainland China its largest market at approximately 41.3% of net sales.